|
1）Brill A, Fuchs TA, Chauhan AK, et al. D. von Willebrand factor-mediated platelet adhesion is critical for deep vein thrombosis in mouse models. Blood. 2011; 117: 1400-7
|
|
|
|
2）von Bruhl ML, Stark K, Steinhart A, et al. Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo. J Exp Med. 2012; 209: 819-35
|
|
|
|
|
|
3）Ando M, Fukuda I, Ito M, et al. JCS JWG. Guidelines for the diagnosis, treatment and prevention of pulmonary thromboembolism and deep vein thrombosis (jcs 2009): Digest version. Circ J. 2011; 75: 1258-81
|
|
|
|
|
4）Agnelli G, Prandoni P, Santamaria MG, et al. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators. N Engl J Med. 2001; 345: 165-9
|
|
|
|
|
|
5）Agnelli G, Prandoni P, Becattini C, et al. Extended oral anticoagulant therapy after a first episode of pulmonary embolism. Ann Int Med. 2003; 139: 19-25
|
|
|
|
|
|
6）Sharma A, Chatterjee S, Lichstein E, et al. Extended thromboprophylaxis for medically ill patients with decreased mobility: Does it improve outcomes? J Thromb Haemost. 2012; 10: 2053-60
|
|
|
|
|
|
7）Brighton TA, Eikelboom JW, Mann K, et al. Low-dose aspirin for preventing recurrent venous thromboembolism. N Engl J Med. 2012; 367: 1979-87
|
|
|
|
|
|
8）Becattini C, Agnelli G, Schenone A, et al. Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med. 2012; 366: 1959-67
|
|
|
|
|
|
9）Agnelli G, Buller HR, Cohen A, et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013; 368: 699-708
|
|
|
|
|
|
10）Jerjes-Sanchez C. Venous and arterial thrombosis: A continuous spectrum of the same disease? Eur Heart J. 2005; 26: 3-4
|
|
|
|
|
|
11）Wisler JW, Becker RC. Oral factor Xa inhibitors for the long-term management of ACS. Nat Rev Cardiol. 2012; 9: 392-401
|
|
|
|
|
|
12）Nieswandt B, Pleines I, Bender M. Platelet adhesion and activation mechanisms in arterial thrombosis and ischaemic stroke. J Thromb Haemost. 2011; 9 Suppl 1: 92-104
|
|
|
|
|
|
13）Sevitt S. The structure and growth of valve-pocket thrombi in femoral veins. J Clin Pathol. 1974; 27: 517-28
|
|
|
|
|
|
14）Fuchs TA, Brill A, Wagner DD. Neutrophil extracellular trap (net) impact on deep vein thrombosis. Arterioscler Thromb Vasc Biol. 2012; 32: 1777-83
|
|
|
|
|
|
15）Clark SR, Ma AC, Tavener SA, et al. Platelet TLR4 activates neutrophil extracellular traps to ensnare bacteria in septic blood. Nat Med. 2007; 13: 463-9
|
|
|
|
|
|
16）Brill A, Fuchs TA, Savchenko AS, et al. Neutrophil extracellular traps promote deep vein thrombosis in mice. J Thromb Haemost. 2012; 10: 136-44
|
|
|
|
|
|
17）Martinod K, Demers M, Fuchs TA, et al. Neutrophil histone modification by peptidylarginine deiminase 4 is critical for deep vein thrombosis in mice. Proc Natl Acad Sci U S A. 2013; 110: 8674-9
|
|
|
|
|
|
18）Demers M, Krause DS, Schatzberg D, et al. Cancers predispose neutrophils to release extracellular DNA traps that contribute to cancer-associated thrombosis. Proc Natl Acad Sci U S A. 2012; 109: 13076-81
|
|
|
|
|
|
19）Caudrillier A, Kessenbrock K, Gilliss BM, et al. Platelets induce neutrophil extracellular traps in transfusion-related acute lung injury. J Clin Invest. 2012; 122: 2661-71
|
|
|
|
|
|
20）Thomas GM, Carbo C, Curtis BR, et al. Extracellular DNA traps are associated with the pathogenesis of TRALI in humans and mice. Blood. 2012; 119: 6335-43
|
|
|
|
|
|
21）Watson HG, Chee YL. Aspirin and other antiplatelet drugs in the prevention of venous thromboembolism. Blood Rev. 2008; 22: 107-16
|
|
|
|
|
|
22）Hovens MM, Snoep JD, Tamsma JT, et al. Aspirin in the prevention and treatment of venous thromboembolism. J Thromb Haemost. 2006; 4: 1470-5
|
|
|
|
|
|
23）Antithrombotic Trialistsʼ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002; 324: 71-86
|
|
|
|
|
|
24）Falck-Ytter Y, Francis CW, Johanson NA, et al. Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141: e278S-325S
|
|
|
|
|
|
25）Toyoda K, Yasaka M, Iwade K, et al. Dual antithrombotic therapy increases severe bleeding events in patients with stroke and cardiovascular disease: A prospective, multicenter, observational study. Stroke. 2008; 39: 1740-5
|
|
|
|
|
|
26）Schulman S, Kearon C, Kakkar AK, et al. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med. 2013; 368: 709-18
|
|
|
|
|